Balchem CORP (BCPC) — SEC Filings

Q: What are the key financial highlights for Balchem CORP?

Key financial highlights for Balchem CORP are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Balchem CORP?

Key executives at Balchem CORP are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Balchem CORP stock?

Risk factors for Balchem CORP (BCPC) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Balchem CORP?

Forward-looking statements and predictions from Balchem CORP are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Balchem CORP. Recent 8-K filing on Dec 10, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Balchem CORP on SEC EDGAR

Overview

Balchem CORP (BCPC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 10, 2025: Balchem Corporation filed an 8-K on December 10, 2025, reporting events that occurred on December 9, 2025. The filing is related to Regulation FD Disclosure and Financial Statements and Exhibits. The company is incorporated in Maryland and headquartered in Montvale, NJ.

Sentiment Summary

Across 24 filings, the sentiment breakdown is: 2 bullish, 22 neutral. The dominant filing sentiment for Balchem CORP is neutral.

Filing Type Overview

Balchem CORP (BCPC) has filed 9 8-K, 6 10-Q, 1 DEFA14A, 2 10-K, 5 SC 13G/A, 1 DEF 14A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (24)

Balchem Corp Files 8-K: Regulation FD & Financials — 8-K · Dec 10, 2025 Risk: low
Balchem Corporation filed an 8-K on December 10, 2025, reporting events that occurred on December 9, 2025. The filing is related to Regulation FD Disclosure and
Balchem's Q3 Earnings Soar 19% on Strong Sales Growth — 10-Q · Oct 21, 2025 Risk: low
Balchem Corporation reported robust financial performance for the three and nine months ended September 30, 2025. Net sales increased by 11.5% to $267.56 millio
Balchem's Q2 Soars: Revenue Up 7.2%, Net Income Jumps 15.8% — 10-Q · Jul 31, 2025 Risk: low
BALCHEM CORP reported a robust second quarter for 2025, with revenue reaching $250.5 million, marking a 7.2% increase from $233.7 million in Q2 2024. Net income
Balchem Corp (BCPC) Submits Matter to Security Holders — 8-K · Jun 20, 2025 Risk: low
On June 18, 2025, Balchem Corporation (BCPC) filed an 8-K report indicating that a matter was submitted to a vote of its security holders. The filing does not s
Balchem Corp. Files Proxy Materials — DEFA14A · Apr 25, 2025 Risk: low
Balchem Corp. filed a Definitive Additional Materials proxy statement on April 25, 2025. This filing relates to the company's proxy materials, which are typical
Balchem Corp. Files Q1 2025 10-Q — 10-Q · Apr 24, 2025 Risk: low
Balchem Corp. filed its 10-Q for the period ending March 31, 2025, reporting on its financial performance. The filing details changes in retained earnings, accu
Balchem Corp Reports Director Changes and Officer Compensation — 8-K · Mar 3, 2025 Risk: low
On February 25, 2025, Balchem Corporation (BCPC) filed an 8-K to report the departure of Director Robert J. Kirsch and the election of new Director David M. Mil
Balchem Corp. Files 2024 10-K — 10-K · Feb 21, 2025 Risk: low
Balchem Corp. filed its 2024 10-K on February 21, 2025, reporting on its fiscal year ending December 31, 2024. The company, headquartered in Montvale, NJ, opera
Balchem Corp Announces Executive and Director Changes — 8-K · Feb 14, 2025 Risk: medium
On February 12, 2025, Balchem Corporation (BCPC) announced changes in its executive team and board of directors. The company elected new directors and appointed
Balchem Corp Files 8-K for Regulation FD and Exhibits — 8-K · Dec 10, 2024 Risk: low
On December 9, 2024, Balchem Corporation filed an 8-K report to disclose information regarding Regulation FD and financial statements. The filing does not conta
SC 13G/A Filing — SC 13G/A · Nov 13, 2024
Balchem Corp. Files Q3 2024 10-Q Report — 10-Q · Oct 25, 2024 Risk: low
Balchem Corp. reported its third-quarter results for the period ending September 30, 2024. The company's financial performance for the quarter and year-to-date
Balchem Corp Announces Executive and Director Changes — 8-K · Oct 17, 2024 Risk: medium
Balchem Corporation announced on October 16, 2024, changes in its executive team and board of directors. The filing details the departure of certain officers an
Balchem Corp Announces Board and Executive Changes — 8-K · Sep 20, 2024 Risk: low
Balchem Corporation announced on September 18, 2024, changes related to its board of directors and executive compensation. The filing indicates the departure of
Balchem Corp. Files 10-Q for Q2 2024 — 10-Q · Jul 26, 2024 Risk: medium
Balchem Corp. reported its second quarter 2024 results, with net sales for the six months ended June 30, 2024, and June 30, 2023, showing a decrease. The compan
Balchem Corp Stockholders Vote on Key Matters at Annual Meeting — 8-K · Jun 24, 2024 Risk: low
On June 20, 2024, Balchem Corporation (BCPC) filed an 8-K report to announce the results of its 2024 Annual Meeting of Stockholders. The company reported that i
Balchem Corp. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 3, 2024 Risk: low
BALCHEM CORP (BCPC) filed a Quarterly Report (10-Q) with the SEC on May 3, 2024. Balchem Corp. filed its 10-Q report for the quarterly period ended March 31, 20
Balchem Corp. Announces 2024 Annual Meeting of Shareholders on June 20, 2024 — DEF 14A · Apr 26, 2024 Risk: low
BALCHEM CORP (BCPC) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Balchem Corporation will hold its 2024 Annual Meeting of Shareholders virt
Balchem Corp Reports Director Changes and Officer Compensation — 8-K · Mar 29, 2024 Risk: low
Balchem Corporation announced on March 25, 2024, the departure of director Dr. Robert L. Shapiro and the election of new director Dr. Mary E. Miller. The compan
Balchem Corp. Files 2023 Annual Report on Form 10-K — 10-K · Feb 16, 2024 Risk: medium
BALCHEM CORP (BCPC) filed a Annual Report (10-K) with the SEC on February 16, 2024. Balchem Corp. filed its 2023 Form 10-K on February 16, 2024. The filing cove
Vanguard Amends Balchem Stake: 1.8% Shared Voting Power — SC 13G/A · Feb 13, 2024 Risk: low
The Vanguard Group, a major investment firm, filed an amended SC 13G/A on February 13, 2024, updating its beneficial ownership in Balchem Corp. As of December 2
Wasatch Advisors LP Maintains 5.9% Stake in Balchem Corp — SC 13G/A · Feb 9, 2024 Risk: low
Wasatch Advisors LP, an investment adviser, filed an amended Schedule 13G on February 9, 2024, disclosing its ownership of 1,910,409 shares of Balchem Corporati
APG Asset Management Amends Balchem Corp. Stake Filing — SC 13G/A · Feb 7, 2024
APG Asset Management US Inc. filed an amended Schedule 13G/A on February 7, 2024, indicating a change in their beneficial ownership of Balchem Corp. (BCHE) comm
BlackRock Amends Balchem Stake, Maintains Passive Investment — SC 13G/A · Jan 22, 2024
BlackRock Inc. filed an amended SC 13G/A on January 22, 2024, indicating its ownership of Balchem Corporation's common stock as of December 31, 2023. This filin

Risk Profile

Risk Assessment: Of BCPC's 21 recent filings, 0 were flagged as high-risk, 4 as medium-risk, and 17 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Balchem CORP's most recent 10-Q filing (Oct 21, 2025):

Revenue: $267.56M
Net Income: $40.29M
EPS: $1.24
Debt-to-Equity: 0.28
Cash Position: $65.09M
Operating Margin: 20.4%
Total Assets: $1.66B
Total Debt: $166.25M

Key Executives

Robert J. Kirsch
David M. Miller
Dr. Robert L. Shapiro
Dr. Mary E. Miller

Industry Context

Balchem operates in the specialty ingredients sector, serving diverse end markets including human nutrition and health, animal nutrition and health, and specialty products. The industry is characterized by innovation, demand for sustainable and health-focused solutions, and consolidation. Key trends include the growing demand for plant-based ingredients, personalized nutrition, and advanced animal feed additives.

Top Tags

10-Q (4) · financials (4) · institutional-ownership (4) · amendment (4) · governance (3) · executive-compensation (3) · Specialty Chemicals (2) · Nutrition (2) · quarterly-report (2) · officer-compensation (2)

Key Numbers

Net sales for Q3 2025: $267.56M — Increased 11.5% from $239.94M in Q3 2024
Net earnings for Q3 2025: $40.29M — Increased 19.1% from $33.84M in Q3 2024
Diluted EPS for Q3 2025: $1.24 — Increased from $1.03 in Q3 2024
Net sales for nine months ended Sept 30, 2025: $773.54M — Increased 8.3% from $713.68M in 2024
Net earnings for nine months ended Sept 30, 2025: $115.62M — Increased 21.8% from $94.89M in 2024
Diluted EPS for nine months ended Sept 30, 2025: $3.54 — Increased from $2.90 in 2024
Cash and cash equivalents as of Sept 30, 2025: $65.09M — Increased from $49.52M at Dec 31, 2024
Revolving loan balance as of Sept 30, 2025: $154.00M — Decreased from $190.00M at Dec 31, 2024
Total stockholders' equity as of Sept 30, 2025: $1.30B — Increased from $1.15B at Dec 31, 2024
Foreign currency translation adjustment for nine months ended Sept 30, 2025: $65.58M — Significant contributor to comprehensive income
Q2 2025 Revenue: $250.5M — Increased by 7.2% from Q2 2024
Q2 2025 Net Income: $35.2M — Increased by 15.8% from Q2 2024
Revenue Growth: 7.2% — Year-over-year increase for Q2 2025
Net Income Growth: 15.8% — Year-over-year increase for Q2 2025
Human Nutrition & Health Revenue Growth: 9.5% — Segment growth in Q2 2025

Forward-Looking Statements

{"claim":"Vanguard will maintain its passive investment strategy in Balchem Corp.","entity":"The Vanguard Group","targetDate":"Next 12 months","confidence":"high"}
{"claim":"Wasatch Advisors LP will maintain a significant stake in Balchem Corporation for the foreseeable future.","entity":"Wasatch Advisors LP","targetDate":"12-2024","confidence":"medium"}

Related Companies

DSM · BASF

Frequently Asked Questions

What are the latest SEC filings for Balchem CORP (BCPC)?

Balchem CORP has 24 recent SEC filings from Jan 2024 to Dec 2025, including 9 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of BCPC filings?

Across 24 filings, the sentiment breakdown is: 2 bullish, 22 neutral. The dominant sentiment is neutral.

Where can I find Balchem CORP SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Balchem CORP (BCPC) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Balchem CORP?

Key financial highlights from Balchem CORP's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for BCPC?

The investment thesis for BCPC includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Balchem CORP?

Key executives identified across Balchem CORP's filings include Robert J. Kirsch, David M. Miller, Dr. Robert L. Shapiro, Dr. Mary E. Miller.

What are the main risk factors for Balchem CORP stock?

Of BCPC's 21 assessed filings, 0 were flagged high-risk, 4 medium-risk, and 17 low-risk.

What are recent predictions and forward guidance from Balchem CORP?

Recent forward-looking statements from Balchem CORP include guidance on {"claim":"Vanguard will maintain its passive investment strategy in Balchem Corp.","entity":"The Vanguard Group","target and 1 other predictions.